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Abstract The effect of VLDL on plasminogen activator
inhibitor type 1 biosynthesis in HepGZ cells was investigated.
Exposure of HepG2 cells to VLDL (range, 10 to 100 g.g protein
per milliliter) for 16 hours resulted in an enhanced release of
PAI-I antigen and PAI activity into conditioned medium,
accompanied by the accumulation of intracellular triglycerides.
By using a monoclonal antibody (IgG C7) specific to the LDL
receptor, we showed that the effect of VLDL is mediated by its
interaction with the LDL receptor. Enhanced PAI-I release
was due to increased biosynthesis: PAI-1 mRNA was doubled,
mainly because of the efiect on the 2.2-kb PAI-I mRNA rather
than the 3.2-kb transcript. Addition of insulin with the VLDL
fflissue plasminogen activator initiates fibrinolysis
I bV activation o[ plasminogen to plasmin in as-I sociation with fibrin.r'2 The activity of TPA is
regulated by its major physiological inhibitor, PAI-1.3
Much evidence indicates that elevated levels of PAI-1
are associated with the incidence of atherothrombotic
episodes.a Moreover, elevated levels of PAI-1 are asso-
ciated with obesity,5 non-insulin-dependent diabetes,"
and/or insulin resistanceT and, more generally, with the
features of syndrome X.E
Epidemiological studies suggest that elevated plasma
triglycerides constitute a risk factor for vascular disease.e
In the Framingham Study, men and women with triglyc-
eride levels >1.7 mmol/L and HDL levels <1.03 mmol/L
had a high rate of coronary heart disease,lo and the
PROCAM study showed hypertriglyceridemia to be a
powerfil risk factor when combined with a high ratio
(>5.0) of plasma LDL to HDL cholesterol.ll
In hypertriglyceridemic patients, the plasma fìbrino-
lytic capacity is reduced because of elevated levels of
PAI-1 in plasma,r2-1s and a direct correlation between
triglyceride leveis and PAI-1 activity or antigen has been
reported.ìs'16
The synthesis of PAI-1 by endothelial, smooth muscle,
or liver cells is regulated by several substances.'7 To
explain the link between PAI-1 and plasma triglyceride
levcls, studies in human umbilical vein enclothelial cells
have been performed.ls'r8 The results indicate that
VLDL, the major lipoprotein subfraction responsible for
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further enhanced PAI-I antigen release and PAI-1 mRNA
accumulation. The effect of VLDL on steady state levels of
PAI-1 mRNA was apparently not due to an increase of gene
transcription but to stabilization of both PAI-1 mRNA tran-
scripts. The enhancing effect of VLDL on PAI-1 biosynthesis
in HepG2 cells may raise PAI-I antigen levels not only in
hypertriglyceridemic states but also in those conditions in
which both insulin and VLDL are elevated. (Arterioscler
Thromb Vasc Biol. 1996;16:89-96.)
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triglyceride transport, increases PAI-1 biosynthesis in
endothelial cells. This effect is more pronounced when
cells are incubated with VLDL isolated from plasma of
hypertriglyceridemic patients, which suggests a direct
effect of the lipoprotein on PAI-1 antigen biosynthe-
sis.rs,18 The greater effect of VLDL from hypertriglycer-
idemic patients than that from normolipidemic subjects
may be due to the presence in the former of larger
VLDL particles containing newly transferred apoE that
have high affinity for the apoB/E receptor present on
endothelial cells.l8
'We have previously demonstratedls'1e that VLDL
from both normal subjects and hypertriglyceridemic
patients increases the release of PAI-1 antigen by
HepG2 cells, a hepatoma cell line that possesses most of
the characteristics of human hepatocytes. This athero-
genic lipoprotein subfraction may thus be directly in-
volved, by an as yet unidentified mechanism, in the
regulation of PAI-1 biosynthesis not only in the vascular
tree but also in the liver.
In this study we show that VLDL increases PAI-1
biosynthesis by HepG2 cells in vitro through an intcrac-
tion with the LDL receptor, influencing PAI-l mRNA
accumulation, mainly via (a) posttranscriptional mecha-
nism(s). This effect is further enhanced by insulin, a
known inducer of PAI-l biosynthesis.20
Methods
Materials
All disposable materials were from Costar; Hybond N filters,
random primcr kit (Multiprimc DNA labeling systcm), and rrP-
labeled dCTP and UTP werc from Amersham Corp. All thc
culturc mcdia, antibiotics, and arnino acids were from GIBCO
[,ab. PMSF, cycloheximide, actinomycin D, bovinc insulin, and
aprotinin were purchascd fiom Sigma Chcmical Co.
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Selected Abbreviations and Acronyms
apo 
- 
apolipoprotein
LRP 
- 
LDL receptor-related protein
PAI-1 
- 
plasminogen activator inhibitor type-l
poly(A) = polyadenylalion
TPA : tissue-type plasminogen activator
0.15 mol/L NaCl, 50 mg/ml BSA, and 0.2% lvollvollTween 20)
and then for 2 hours at room temperature in 50 mL of buffer A
containing 15 pglml- mouse IgG-C7, a monoclonal antibody
anti-LDL receptor (Amersham). The nitrocellulose was then
washed at room temperature with 200 mL of 10 mmol/L
Tris-HCl and 0.15 mol/L NaCl at pH 7 .4, containing 0.1 7o SDS,
17a Nonidet P-40, and 0.57o sodium deoxycholate (buffer B).
The washed nitrocellulose paper was then incubated for 30
minutes at room temperature with 50 mL of buffer A contain-
ing peroxidase-conjugated rabbit immunoglobulins directed
against mouse immunoglobulins (Dako Denmark) diluted
1:5000. The membrane was then rinsed and washed with buffer
4 LDL receptor protein on nitrocellulose membrane wasdetected by using a light-emitting nonradioactive meihod of
detection (ECL, Amersham) on Western blotting.
To analyze the efect of the monoclonal antibody against the
LDL receptor (C7) on Vl-Dl--induced release of pAI-l, we
first incubated HepG2 cells with serum-free medium contain-
ing 15 pglml oî C7 or equal amounts of nonimmuno mono-
clonal antibody for 2 hours at 37"C. VLDL was added at a final
concentration of 100 p,g/ml-, and the amount of PAI-1 released
was determined after 16 hours.
Quantitation of PAI-l Antigen and Activity
The PAI-1 concentrations were determined by ELISA (F1-5
Monozyme) and the activity by a two-stage indirect chromo-
genic assay (Ortho Diagnostica System).2a One unit of inhibi-
tory activity was defined as the amount of sample required to
inhibit 1 IU of TPA. The possible interference of the lipopro-
teins with the assay systems was excluded on the basis of
experiments in which PAI-1 was determined in medium con-
taining different concentrations of Iipoproteins.
Determination of Cellular Trigtyceride Content
Layers of HepG2 cells were washed three times with buffer
containing 0.15 mol/L NaCl, 50 mmol/L Tris (pH 7.4), and,
0.2% BSA and three more times with the same buffer without
BSA. Lipids \/ere extracted from cell monolayers by the
hexane-isopropanol method,25 ie, 2 mLof hexane-isopropanol
mixture (3:2 vol/vol) was added to cell monolayers for ]0
minutes at room temperature, and îhe solvent was transferrdd
to a glass tube and dried under Nr. Triglycerides were deter-
mined by enzymatic methods after dissolving the lipids in
isopropanol using a commercial kit (Boehringer Mannheim
GmbH Diagnostica IC).
Preparation of RNA and Northern Blot Analysis
Total cellular RNA was obtained according to Chomczynski
and Sacchi.26 Bricfly, 10 to 20 /ag oî total RNA, determined
spectrophotometrically, was subjected to electrophoresis in
formaldehyde-agarose gel.27 Samples were then transferred to
the nylon membrane Hybond Nt (Amersham) by capillary
blotting. Membrancs were first hybridized for at least 4 hours at
42"C and then hybridized overnight at the same temperature in
50'lo formamide, SSPE 5x (0.75 mot/L NaCl, 0.05 mol/L
NaH2POa'HrO, 5 mmol/L EDTA), Denhardt's solurion 4X,
1t)0 mg/ml dextran sulfate, 100 pglml- salmon sperm DNA,
and 200 p.g/ml- baker's yeast tRNA. Hybridization was per-
fbrmed with cDNA probes labeled with frp]dCTp to 5X 108 to
I x 10' cpm/p.g of DNA by the random primer method. Mem-
branes were then washed four times for 30 minutes at 42.C
(two washes with SSPE 5x, one with SSPE 1x conraining SDS
0.1Vo, and onc with SSPE 0.1X containing SDS 0.1%). Bands
wcre quantified by exposing thc membranes to autoradiogra-
phy lìlm (Hyperfìlm MP, Amersham) with intensifying screens
at 80'C and densitometry. The data were expressecl as
amounts of PAI-1 mRNA relative to GAPDH mRNA, which
was not infìuenced by VLDL treatment. The probe used for
PAI-I was a human 2.2-kb EcoRl-Bam Hl cDNA frasment2s
kindly provided by Dr A. Riccio (International Institute ot
Genetics and tsiophysics, National Council of Research, Na-
Lipoprotein Isolation
Blood, obtained from normolipidemic subjects after over-
night fasting, was anticoagulated with Na, EDTA (lmg/ml)
containing 10 kallikrein units per milliliter (KU/mL) aprotinin
and kept on ice. Plasma was separated by low speed centrifu,
gation (6009) at 4'C, and VLDL isolation was started within 6
hours after blood collection. Plasma containing 50 KU/mL
aprotinin and l0 mmol/L PMSF was layered under 1.006 g/ml-
KBr density solution containing 0.15 mol/L NaCl, 1 mmol/L
Na, EDTA, and 3 mmol/L NaN3 (pH 7.4) and centrifuged in a
Beckman Ti 50.2 rotor (40 000 rpm) for 20 hours at 4'C. VLDL
particles that floated to the top were then removed, steriiized
through a 0.45-1tm filter (Millipore Corp), stored in sterile
tubes at 4'C, and used within 2 weeks of isolation. LDL
(density range, 1.020 to 1.050 g/ml) and HDL (density rangc,
i.06 to 1.2i g/ml-) were prepared by dillerential ultracentrifu-
gation.2r LDL and HDL were exhaustively dialyzed at 4'C
against phosphate bufer consisting of 0.15 mol/L NaCl and 1
mmol/L Na, EDTA (pH 7. ). The dialyzed lipoprotein fiac-
tions were sterilized by passage through Millipore filters (0.22
g,m; Millipore Corp), stored in sterile tubes at 4'C, and used
within 2 weeks. Total protein content in lipoprotein prepara-
tions was analyzed by the Lowry method.22
Cell Culture Experiments
HcpG2 cells were cultured in minimal essential medium
supplemented with 10Vo heat-inactivated fetal calf serum con-
taining 2 mmol/L r--glutamine, 100 IU/mL penicillin, 100
mg/ml streptomycin, 2.2 mglL sodium bicarbonate, and 1
mmol/L sodium pyruvate under a humidified atmosphere of
95Vo airl57o COrat37"C. The cell line was tested for and found
frce of mycoplasm infection (Mycoplasma detection kit, Boeh-
ringer Mannheim GmbH). The cells received fresh complete
medium every 3 days and were passaged 1:5 on a 7-day cycle.
For experimental purposes, HepG2 cells were plated at the
density of 1.3 to 1.5x10ó cells in 250-mm2 flasks and used at
confluence, which was attained within 6 to 7 days. Cells, which
were reted with serum-free medium for 40 hours before the
experiments, were then washed three times with PBS and
incubated in serum-free medium with or without diferent
agents. After appropriate incubation times, conditioned medium
was collected and centrifuged to removc cell debris, and samples
wcre stored at 
-20'C until analyzed for PAI-1. Cells were washed
in ice-cold PBS and dissolved with guanidine isothioryanate
sarcosyl solution for total cellular RNA extraction.
Immunoblotting of LDL Receptor
For blotting experiments, cell layers seeded in 750-mm2
flasks werc kept for 24 hours in serum-free medium. Cells were
then washed three times with PBS. scraoed oll with a rubber
spatula, and centrifuged at 2009 for 5 mìnutes. and the pellet
was solubilized by addition of a bufer containing 50 mmol/L
Tris-HCt, 2 mmollL CaClr, 80 mmol/L NaCl, 5 mmol/L benz-
amidine, I mmol/L PMSF, 0.5 pmolll. leupeptin, and l.\a/o
Triton X-100. The solubilized proteins wcre centrifuged at
3000009 (Beckman TLA 100.1 rotor) for 40 minutcs at 4'C,
and the supernatants were then subjected to one-dimensional
SDS-polyacrylamide gcl electrophoresis on 3o/o to 15a/o gels,
the proteins being transferred from the gels onto nitrocellulosc
paper.23 Thc nitrocellulose paper was incubatcd lbr 60 minutes
at 37"C in 50 mL of buffer A (i0 mmol/L Tris-HCl af pH 7.4,
ples, Italy) and a 1.4-kb BamHl cDNA fragment of human
GAPDH kindly provided by Dr P. Castelli (Consorzio Mario
Negri sud, Santa Maria Imbaro, Chieti, Italy). All probes werc
isolated by agarose-gel electrophoresis and purified by using
the gene clean kit (Bio 101, Inc).
Run-on Assay of RNA Transcripts
Isolation of nuclei, transcription run-on, and isolation of
nascent RNA transcripts were performed according to Green-
berg and Ziff,2e w'th minor modifìcations.3o Nuclei isolated
from stimulated and control cells were resuspended in 250 ptL
ice-cold buffer (50 mmol/L Tris-HCl, pH 8.3; 407o glycerol; 5
mmol/L MgClr; 0.1 mmol/L EDTA, pH 8). For run-on assay,
equal numbers of nuclei (5 to 10x106) were incubated for 30
minutes at 30'C in 300 pr,L reaction buffer containing 25
mmol/L Tris-HCl, pH 8; 12.5 mmol/L MgCl; 750 mmol/L KCI;
1.25 mmol/L each of GTP, CTP, and ATP; and 100 g,Ci of
[o-r'zPìUTP (3000 Cilmmol, Amersham Internarional). Elon-
gated transcripts were isolated by the guanidine/cesium proce-
dure, with 50 pg of yeast IRNA added as the carrier.3r The
RNA pellet was resuspended in 180 pL of ice-cold TNE (0.5
mmol,{L Tris-HCl, pH 8; 1.5 mol/L NaCl), denatured with 20
p,L ot 2 N NaOH on ice for 10 minutes, and then neutralized
by the addition of HEPES, pH 7.2 (0.48 mmol/L final concen-
tration). RNA was then precipitated by adding 880 pL ethanol,
the pellet was resuspended in 100 p,L hybridization solution (10
mmol,ll- TES,2% SDS, 10 mmol/L EDTA, 300 mmol/L NaCl),
and radioactivity was measured. Equal quantities of labeled
RNA transcripts fiom stimulated and control nuclei were
hybridized to DNA immobilized on nitrocellulose filters at
65"C for 48 hours. Filters were then washed three times (30
minutes each) with 0.2X SSC at 65'C and incubated at 37'C for
30 minutes in 0.2x SSC with I pglmL RNase A (Boehringer
Mannheim) before exposure for autoradiography. For DNA
immobilization on filters, plasmid DNA (5 prg) was denatured
with 0.3 mmol,/L NaOH at 60"C for 30 minutes. neutralized
with ammonium acetate (4 mol/L final concentration), and
spotted onto nitrocellulose filters (Schleicher & Schuell) using
a slot-blot apparatus.
Determination of PAI-1 mRNA Half-life
Actinomycin D (10 pglml-) was added (time 0) to HepG2
cells after overnight incubation with or without 10t) pg of
protein per milliliter VLDL. Celts were harvested at specific
ttmes and total cellular RNA was isolated. Northern blot
analysis was pcrformed as described above.
Statistical Analysis
Data are exprcssed as mean+SEM. Comparisons betwcen
trcatmcnt conditions were made bv Student's paired r test.
Results
HepG2 cells, incubated for 16 hours in serum-free
mcdium, released 13.6-1_ 1.8 ng/ml PAI-1 antigen,
whergas thosc incubated with a physiological concentra-
tion of VLDL (100 pr.g protein pcr milliliter) released
25.9 r 3.t1 ng/ml (P<.001) of PAI-1 antigen, and PAI
activity doubled, indicating that PAI-1 released in this
condition was in its astive lbrm fTablc). More marked
incrcases in PAI-1 antigen release were detected in
subconfluent than in conflucnt cells (+165+19o/o ancl
+ 61 + 4ak, respectively; n:3).
This concentration of added VLDL also increasecl
the intracellular accumulation of trislvccrides(+37.3'rI.1%, n:3), reflecting both uptakJ àncl pro-
ccssing of the VLDL, and this effect was more marked in
subconfluent cclls (+ 112'r23ok, n:3). Wc hypothesized
thiit the elÌect of VLDL on PAI-l release was mcdiated
by an interrìction of VLD[- with the LDL receptor
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Efiect of VLDL on PAI-1 Antigen and Activity in
Conditioned Medium of HepG2 Cells
PAI-1
Antigen,
ng/ml (n=13)
91
PAI Activity,
lU/mL (n=5)
Untreated cells
VLDL-treated cells
'13.6+1.8
25.9+3.8
5.9+1.0
10.8*2.3
Values are meanlsEM of separate experiments (n) performed with
individual VLDL oreparations. HeoG2 cells were incubated for 16 hours
with serum-free medium (untreated cells) or that containing 100 pg
protein per milliliter VLDL (VLDL{reated cells).
present on HepG2 cells. HepG2 cells were therefóre
incubated for 2 hours with 15 pglmL of a monoclonal
anti-LDL receptor antibody (mouse IgG C7) before
being incubated tbr 16 hours in serum-free medium with
or without 100 g.g protein per milliliter VLDL. Prior
experiments had established that the C7 antibody was
specific for the LDL receptor (Fig 1). Exposure of
HepG2 cells to the C7 antibody, but not to a nonim-
muno antibody, prevented the enhancing effect of
VLDL on PAI-1 release (enhancements 92%,23Vo, and
100Vo over control for VLDL, VLDL+C7, and VLDL+
nonimmuno antibody, respectivcly).
The mechanisms involved in the effect of VLDL on
PAI-1 biosynthesis in HepG2 cells were investigated.
Northern blot analysis showed that VLDL isolated from
13 different individuals doubled the levels of PAI-1
mRNA in HepG2 cells under the above condition, the
increase being mainly due to accumulation oî the 2.2-kb
PAI-1 mRNA transcript (Fig 2). The possibility that the
effect of VLDL on PAI-1 biosynthesis was due to
contamination of the lipoprotein subfraction with bac-
terial lipopolysaccharide was excluded, ie, incubation
with 10 pglmL of lipopolysaccharide did not influence
PAI-I mRNA expression (data not shown) or PAI-1
release into the medium.17'32
We then incubated HepG2 cells with serum-free
medium containing increasing concentrations of VLDL
<500K
<97 K
AB
Ftc 1. SDS-polyacrylamide gel electrophoresis and immuno-
blotting of LDL receptor in HepG2 cells. After incubation for 16
hours in serum-free medium, cells were solubilized, and 200 pg
of protein in detergent extracts was subjected to electrophore-
sis. The proteins were transferred to nitrocellulose paper and
incubated with monoclonal anti-LDL receptor antibody (1 5
pglml of mouse lgG C7). Molecular weight standards are
indicated. The LDL receptor preparations were derived from
HepG2 cells (A) and normal human fibroblasts (B).
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total 2.2Rb 3.2 kb
PAI.1 MRNA
(10 to 100 pg protein per milliliter). VLDL induced a
concentration-dependent increase in the 2.2-kb PAI-1
mRNA transcript, with a minor effect on the 3.2-kb
transcript (Fig 3). Time-course experiments indicated no
appreciable change in PAI-1 mRNA expression over 24
hours in control cells. In contrast, in the presence of 100
p,g protein per milliliter VLDL, enhancement of 2.2-kb
PAI-1 mRNA was recorded afî"er t hours of incubation,
with no effect on the 3.2-kb PAI-1 mRNA over 24 hours
ldata not shown).
0 10 100
VLDL( pg protein/ml)
Frc 3. Effect of difierent concentrations of VLDL on PAI-1
mRNA expression in HepG2 cells, which were incubated for 16
hours in serum-free medium in the absence or oresence of
different concentrations of VLDL (10 to 100 pg protein per
milliliter). Total RNA was extracted, analyzed by Nodhern blot-
ting (10 pg of total RNA per lane), and probed with a PAI-1 cDNA
and GAPDH cDNA fragment. The data represent mean+SEM of
PAI-1 mRNA relative values over control, determined in three
experiments performed with individual VLDL preparations. The
inset shows a representative Nodhern blot of control cells (C)
and those incubated with different concentrations of VLDL (10 to
100 pg protein per milliliter).
-t ;ffi Frc2. Effect of VLDL on PAI-1 mRNAexpression in HepG2 cells. HePG2cells (3 to 4x106 cells) were incubated
for 16 hours with serum-free medium
in the absence or presence of VLDL.
Total RNA was extracted, analyzed by
Northern blotting (10 pg of RNA Per
lane), and hybridized with PAI-1 and
GADPH probes. The intensity of the
bands on autoradiographic films was
quantified by densitometric scanning,
and PAI-1 mRNA amounts were nor-
malized against the corresponding
GAPDH signal. The bars represent the
mean:tsEM of PAI-1 mRNA relative
value over control, determined in 13
experiments performed with individual
VLDL preparations ('100 pg protein per
milliliter). In the inset is shown a repre-
sentative Northem blot of untreated
cells (c) and those treated with 100 pg
protein per milliliter of VLDL isolated
from two different donors (subjects a
and b). The top two bands are 3.2- and
2.2-kb PAI-1 mRNA, and the bottom
band is 1.4-kb GAPDH mRNA.
rtil
The effect of VLDL on PAI-1 biosynthesis was com-
pared with that of HDL and LDL (100 pg protein per
milliliter). Neither LDL nor HDL influenced PAI-1
mRNA expression (Fig a); VLDL alone among lipopro-
tein subfractions enhanced the accumulation of PAI-1
mRNA.
To determine whether the effect of VLDL on PAI-I
mRNA expression required protein synthesis, cells were
incubated with 25 pglmL cycloheximide in the presence
or absence of 100 pg protein per milliliter VLDL. In the
absence of VLDL, cycloheximide caused a net induction
of the 3.2-kb without affecting the 2.2-kb transcript (Fig
5), confirming data reported by others,33,3a whereas
VLDL induced the expected accumulation of the 2.2-kb
PAI-1 mRNA. Cycloheximide and VLDL, added to-
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Frc 4. ef""t Jt different classes of lipoproteins on PAI-1 mRNA
expression in HepG2 cells. A representative Northern blot of
HeoG2 cells incubated for 16 hours in serum-free medium in the
absence or presence of 100 pg protein per milliliter of different
lipoprotein fractions (VLDL, LDL, or HDL) is shown. Total PAI-1
mRNA (3.2- plus 2.2-kb transcripts) were normalìzed against the
corresponding 1.4-kb GAPDH signal.
o
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Frc 5. Effect of cycloheximide on PAI-1 mRNA expression in
VLDl-treated HepG2 cells, which were incubated in serum-free
medium for 16 hours with 1 00 pg protein per milliliter VLDL in the
absence or presence of cycloheximide (25 pglml). Total RNA
was extracted, analyzed by Northern blotting (10 pg of total RNA
per lane), and probed with a PAI-1 cDNA and GAPDH cDNA
fragment. Molecular-weight markers in kilobases are shown to
the left. A representative blot from a total of three separate
experiments is shown. CHX indicates cycloheximide.
gether to HepG2 cells, induced upregulation of both
PAI-1 mRNA transcriPts.
HeoG2 cells were next incubated with VLDL plus
insulin. Insulin has been shown to increase PAI-1 syn-
thesis and PAI-1 mRNA accumulation in HepG2 cells
by stabilizing the 3.2-kb PAI-1 transcript.3a It was there-
fore of interest to determine whether VLDL, which
specifically increases the 2.2-kb PAI-1 mRNA transcript,
còuld interfere with the effect of insulin on PAI-I
mRNA expression. A representative Northern blotting
of HepG2 cells treated with VLDL andloÍ insulin is
shown in the inset of Fig 6. VLDL (100 p.g protein per
milliliter) doubled the 2.2-kb PAI-I mRNA, with no
effect oú the 3.2-kb PAI-I mRNA, whereas insulin
increased the expression of both transcripts. Interest-
ingly, the combination of the two stimuli induced a
further enhancement of the 2.2-kb PAI-1 mRNA species
over that of either agent alone. The effect of the
combination of the two agents on the 3.2-kb PAI-1
mRNA was more complex, in that VLDL hampered the
enhancement of the 3.2-kb PAI-1 nRNA induced by
PAr-1 b*
GAPDH
Frc 7. Effect of VLDL on PAI-1 gene transcription. Slot-blot of
transcription run-on studies represents three experiments per-
formed in duplicate with similar results. Nuclei were isolated
from HepG2 cells treated with VLDL (100 pg protein per milliliter)
for the indicated times. pBR322 was used as the negative
control. Run-on reactions and hybridization of the purified run-
on RNA to the indicated plasmid DNA were performed as
described under'Methods.'
insulin (Fig 6), confirming the tendency of VLDL to
increase the shorter transcript alone, also in the pres-
ence of an agent inducing the stabilization of the longer
one. The combination of VLDL and insulin also en-
hanced PAI-1 protein synthesis more than either agent
alone. In fact, PAI-1 levels were increased twofold and
fivefold by VLDL and insulin, respectively, but sidold by
the combination (Fig 6).
We then investigated whether the Vl-Dl--induced
increase in PAI-1 mRNA was the result of transcrip-
tional or posttranscriptional mechanisms. The transcrip-
tional activity of the PAI-1 gene was evaluated in run-on
experiments performed with nuclei isolated from
HepG2 cells incubated with VLDL (100 pg protein per
milliliter) for various times. Nascent nuclear transcripts
were elongated in the presence of [o-3'zP]UTP and
hybridized. VLDL apparently did not increase the tran-
scription rate of the PAI-1 gene at any time point (Fig
7); nor did VLDL affect transcription of the GAPDH
Fro 6. Effect of insulin on PAI-1 in VLDlìreated
HeoG2 cells. whích were incubated in serum-free
medium for 16 hours with 100 pg protein per
milliliter VLDL in the absence or presence of
insulin (135 nmol/L). Total RNA was extracted
and analyzed by Northern blotting (10 pg of total
RNA per lane) followed by hybridization with
human PAI-1 cDNA and GAPDH cDNA probes. In
the tnset is shown a representative Northern blot
of control (lane 1), VLDL (lane 2)' VLDL plus
insulin (lane 3), and insulin (lane 4). The top two
bands are 3.2- and 2.2-kb PAI-1 mRNA, and the
bottom band is 1.4-kb GAPDH mRNA. PAI-1
mRNA levels (solid bars, 3.2 kb; open bars,2.2
kb) were quantified by densitometry and normal-
ized against the corresponding GAPDH signal.
Levels of PAI-I antigen (hatched bars) were
quantified by ELISA in cell supernatants. The
data are expressed as relative values over control
and reoresent mean+SEM of four individual ex-
periments.
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gene, and no detectable signal was given by the pBR322
used as a negative control (Fig 7).
To determine whether modulation of PAI-1 mRNA
levels by VLDL was due to an induced change in stability
of PAI-1 mRNA, actinomycin D (10 g.g/ml-) was added
to cells previously kept for 16 hours in serum-free
medium with or without 100 p,g protein per milliliter
VLDL. Total cellular RNA was then harvested and
analyzed at selected intervals. In control cells, the half-
lives of the 3.2- and 2.2-kb PAI-1 mRNA species were, in
agreement with previously published data,35 80 and 190
minutes for the 3.2- and 2.2-kb transcripts, respectively
(Fig 8). After exposure of HepG2 cells to VLDL for 16
hours, the half-lives of both species were prolonged, with
a marked stabilization of the 3.2-kb and a doublins of
the half-life of the 2.2-kb species (Fig 8).
Discussion
In this study we show that VLDL, probably interacting
with the LDL receptor on the surface of HepG2 cells,
induces triglyceride accumulation, biosynthesis of PAI-1,
and enhancement of steady state levels of PAI-1 mRNA.
Incubation of HepG2 cells with VLDL at concentra-
tions like those in the plasma of normolipidemic subjects
(10 to 100 pglmL) increases PAI-1 release into condi-
tioned medium. This induction might have functional
significance, since PAI activity increased in our experi-
ments in parallel with PAI-1 concentration. Interest-
ingly, the enhancing effect of VLDL on PAI-1 release
was dependent on cell density, ie, VLDL induced a
greater increase in subconfluent than in confluent cells.
Since cell density has previously been shown to modulate
LDL receptor expression and/or lipoprotein internaliza-
tion,:0,:z it is conceivable that the degree of interaction
of the lipoprotein with the LDL receptor varies accord-
ing to cell density, thereby explaining the difference in
PAI-1 release; indeed, intracellular accumuiation of
triglycerides was highest in cells seeded at low density.
VLDL interacts with HeoG2 cells via both the LDL
receptor and LDL receptor-related protein (LRP).$ By
using a specific monoclonal antibody (C7) directed
against the first cysteine-rich repeat of the LDL recep-
tor,3e we showed that the effect of VLDL on PAI-I
induction depended on interaction specif,cally with the
LDL receptor, since C7 does not recognize LRP. Fur-
thermore, involvement of LRP in the phenomenon is
unlikely, because this receptor recognizes chylomicrons
or apoE-enriched VLDL (B-VLDL), whereas we used
VLDL from normal subjects, which does not normally
bind to LRP.40 Recently another receptor for VLDL has
Fto B. Effect of VLDL on PAI-1 mRNA half-life in
HepG2 cells. HepG2 cells were incubated for 16
hours in the absence (o) or presence (a) of 100 pg
protein per milliliter VLDL. Then actinomycin D (10
pglml) was added to the media, and total cellular
RNA was harvested at selected time intervals and
analyzed as described in 'Methods.' The amounts
of PAI-1 mRNA are expressed as relative ratio over
time 0. A representative time course of decay of
3.2-kb (A) and2.2-kb (B) PAI-1 mRNAtranscripts is
snown.
been described that binds and internalizes apoE-con-
taining lipoproteinsai; this receptor (VLDL receptor)
has been described in skeletal muscle, heart, and kidney
but not in hepatic cells.al
The interaction of VLDL with HeoG2 cells doubled
the steady state levels of PAI-I mRNA. This effect is
consistently observed with VLDL obtained from plasma
of different subjects (n:13) and is dependent on the
concentration of VLDL added to the incubation me-
dium. In contrast, neither LDL nor HDL influenced
PAI-1 antigen or PAI-1 mRNA levels.
VLDL mostly increased the 2.2-kb PAI-I mRNA
transcript, with a minor effect on the 3.2-kb PAI-1
mRNA. Thus, VLDL profoundly changed the ratio
between the two mRNAs in favor of the more stable
transcript. It is known that the 2.2-kbPAI-I mRNA has
a longer half-life than the 3.2-kb species because of the
lack of the AU-rich sequence in the 3'-untranslated
region.+z-+s Phorbol myriitate acetate induces the 2.2-
and 3.2-kb transcripts at 12 and 3 hours, respectively,
which effect decreases in both after 12 hours.a6 In
contrast, VLDL specifically increases the 2.2-kb PAI-1
mRNA transcript in HepG2 cells after 9 to 12 hours of
incubation, and this effect lasts for over 24 hours.
Insulin has been shown to induce overexpression of
PAI-1 mRNA in HepG2 cells as a result of the increase
in steady state levels of the 3.2-kb transcript.3a The
combination of VLDL and insulin resulted, as èxpected,
in more PAI-1 release than with either asent alone. but
whereas the level of 2.2-kb PAI- I mRNÀ was hisher in
cells exposed to the combination of VLDL and insulin,
that of the 3.2-kb transcript was lower than with insulin
alone. These data provide a further, although indirect,
demonstration of the predominant effect of VLDL on
the shorter PAI-1 mRNA transcriot.
VLDL aclded to HepG2 cells èxposed to cyclohexi-
mide produced a marked accumulation of both PAI-I
mRNA transcripts, with ongoing protein synthesis af-
fecting mostly the 3.2-kb species.
Steady state levels of PAI-1 can be affected by factors
that increase gene transcription, PAI-1 mRNA accumu-
lation, or both.17 Applying the run-on assay in our
experimental conditions, we failed to demonstrate any
effect of VLDL on PAI-1 gene transcription, a result
that must be considered with caution, because the
sensitivity of the run-on methodology is low. On the
other hand, VLDL did influence PAI-1 mRNA stability,
prolonging the half-lives of both PAI-1 mRNA tran-
scripts. Increased stabilization of the 2.2-kb PAI-1
mRNA transcript would favor increased PAI-1 biosyn-
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thesis; other mechanisms may be responsible for the
unchanged levels of the 3.2-kb PAI-I mRNA. For
instance, VLDL may influence the termination process
during PAI-1 mRNA transcription in favor of the
shorter transcript. So far, no information is available on
the mechanism(s) involved in the selection of one of the
trvo poly(A) sites in the termination of PAI-1 gene
transcription. Such selection appears to operate in
higher primates, and it has been shown to be dependent
on the presence of cls-acting sequences in the 3'-
untranslated region in the human PAI-1 gene.aT Agents
that are known to induce PAI-1 mRNA accumulation
have been shown to act either through an increase in
gene transcription or through stabilization of PAI-1
mRNA, mostly of the 3.2-kb transcript. Thus, in addition
to affecting PAI-1 mRNA stabilization, VLDLs are the
first agonists so far described that may operate to
influence selection of the poly(A) site.
In conclusion, the evidence indicates that PAI-I
mRNA can be regulated by triglyceride-rich lipoproteins
at concentrations that occur in plasma of normolipi-
clemic subjects. The capacity of VLDL to induce PAI-1
biosynthesis is speciflc to this class of lipoproteins and is
mediated by the interaction of VLDL with the LDL
receptor present on HepG2 cells. The induction of
PAI-1 biosynthesis involves at least two major mecha-
nisms, namely PAI-1 mRNA stabilization and a hitherto
undescribed change in the selection of the two poly(A)
sites in the termination of PAI-I gene transcription in
favor of the shorter 2.2-kb transcript. Even if the phys-
iological role of the two PAI-I mRNA transcripts has
not yet been elucidated, the increase in the level of the
more stable mRNA may be expected to have physiolog-
ical significance in terms of increased PAI-1 biosynthe-
sis. These mechanisms are also operative in the presence
of other agents acting on PAI-1 mRNA stabilization,
such as insulin.
The effect of VLDL on PAI-1 biosynthesis may be
relevant not only in genetic or diet-induced hypertriglyc-
eridemia but also in pathological conditions such as type
II diabetes and more generally in the polymetabolic
syndrome (syndrome X), conditions characterized by
insulin resistance and/or elevated insulin levels as well as
by alterations in lipid metabolism leading to elevated
triglyceride levels.
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